-
2023-508169-34-00
5
Insomnia (ICD-10 F51.0)
-
2024-519638-22-00
5
IgA nephropathy
-
2024-520068-32-00
6
Type 2 diabetes
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-522484-15-00
5
2026-04-27
ER+/HER2- early breast cancer
-
2024-518006-40-00
5
2025-11-13
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
-
2025-520582-51-00
5
2025-10-17
Hormone receptor positive breast cancer
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-518008-33-00
5
2025-11-12
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
-
2024-520290-12-00
6
2025-11-04
Hormone receptor–positive (HRpos)/human epidermal growth factor recept
-
2024-519929-38-00
4
2025-10-27
Metastatic Colorectal Cancer without liver metastases
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-519521-37-01
10
2025-07-30
Acute ischemic stroke
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w